NCT06906380Recruiting
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This study will evaluate the long-term safety of ARD103 cellular therapies
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 49 (estimated)
- First submitted
- 26 Mar 2025
- Start date
- 12 May 2026
- Primary completion date
- 30 May 2040
- Lead sponsor
- ARCE Therapeutics, Inc.
- NCT number
- NCT06906380
What you commit to
- Study type: Observational
- Planned participants: 49
- From 12 May 2026 to the primary completion date, 30 May 2040
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are no specific exclusion criteria for this study
Who the study is looking for
- The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.
- The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.
Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novant Health Cancer Institute Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Novant Health Cancer Institute Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.